B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.
Ephraim S. Casper,Kathy L. Christman,Gary K. Schwartz,Bruce E. Johnson,Murray F. Brennan,Joseph R. Bertino +5 more
TL;DR: Edatrexate, an investigational antifolate, is active in patients with lung cancer, and has cytotoxic activity in human sarcoma cell lines.
Journal ArticleDOI
Obstructive Atelectasis in Patients With Small Cell Lung Cancer: Incidence and Response to Treatment
Andrew K. Vaaler,Joseph M. Forrester,May Lesar,Margaret Edison,David Venzon,Bruce E. Johnson +5 more
TL;DR: In this article, the authors defined the incidence of obstructive atelectasis in patients presenting with small cell lung cancer and their response to treatment and defined the risk of dyspnea, cough, and sputum production before starting treatment and 1, 3, and 6 months later.
Journal ArticleDOI
Imatinib in small cell lung cancer.
TL;DR: No evidence of antitumor activity was observed in this small phase II trial including 19 SCLC patients treated with Imatinib Mesylate, and KIT positivity in tumor samples appeared to be far less common than anticipated.
Journal ArticleDOI
Impact of Graft Volume Reduction for Oversized Grafts After Lung Transplantation on Outcome in Recipients With End-stage Restrictive Pulmonary Diseases
Norihisa Shigemura,Christian Bermudez,Brack G. Hattler,Bruce E. Johnson,Maria Crespo,Joseph M. Pilewski,Yoshiya Toyoda +6 more
TL;DR: An oversized graft may lead to a higher incidence of short-term clinical complications with reduced pulmonary function improvement post-operatively in lung transplantation recipients with end-stage restrictive pulmonary diseases.
Journal ArticleDOI
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.
Pamela M. McMahon,Chung Yin Kong,Bruce E. Johnson,Milton C. Weinstein,Jane C. Weeks,Angela C. Tramontano,Lauren E. Cipriano,Colleen Bouzan,G. Scott Gazelle +8 more
TL;DR: The natural history model underlying the MGH Lung Cancer Policy Model (LCPM) does not include the two‐stage clonal expansion model employed in other CISNET lung models, and the LCPM was used to predict numbers of U.S. lung cancer deaths for ages 30–84 between 1975 and 2000 under four scenarios.